Supplementary Figure S10 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer | Synapse
September 16, 2024
Supplementary Figure S10 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Changes in ctDNA fraction and PSA levels between baseline and 4 weeks on-treatment in relation to the durability of response